is saxenda a glp-1 medication Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy. This milestone launch based on the recent ANDA approval obtained by Cipla's partner, Orbicular. Cipla A Comprehensive Guide to GLP-1

Diagnosing MCAS MCAS is more complex to diagnose and generally requires medical investigation alongside nutritional support

GLP-1 Supplement Market Size, Share & Trends Analysis Report By Product Type (Capsules, Tablets, Powders, Gummies, Others), By Application (Blood Sugar Management, Weight Management, Digestive Health, Others), By Distribution Channel (Drug Stores & Retail Pharmacies, Specialty Stores, Online Stores, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034 Last Updated: May 28, 2026 | Author: Dhanashri B | Format: | Report Code: SR7875DR | Pages: 210 GLP-1 Supplement Market Size & Growth Analysis The GLP-1 supplement market size was valued at USD 2.00 billion in 2025 and is projected to grow from USD 2.23 billion in 2026 to USD 5.52 billion by 2034 at a CAGR of 11.97% during the forecast period (20262034)

Yet, existing and ongoing research is continuing to show a deleterious relationship

Clinical decision support, management, risk detection, prevention, prognosis and diabetes diagnosis (including medical image analysis and subtype classification) are expected to be increasingly dependent on artificial intelligence [154158]

More recent research has also looked into GLP-1RAs beneficial influence on glaucoma but focused on this effect at different time ranges

About this article Cite this article Sharma, N., Soni, R., Sharma, M